EANS-Adhoc: SYGNIS Pharma AG / SYGNIS Pharma AG announces key results of its Phase II trial of AX200 for the treatment of Acute Ischemic Stroke

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Research & Development

15.12.2011

Ad-hoc release

SYGNIS Pharma AG announces key results of its Phase II trial of AX200
for the treatment of Acute Ischemic Stroke

Heidelberg, 15 December 2011 - SYGNIS Pharma AG (Frankfurt:
LIOK; ISIN DE000A1E9B74; Prime Standard) today announces key
results of the Phase II clinical trial (AXIS 2) of AX200 to
treat acute ischemic stroke. The key results on the relevant
primary endpoint, using the modified Rankin Scale (mRS), and
secondary endpoint, using the National Institutes of Health Stroke
Scale (NIHSS), show no improvement in patient outcome relative to
the placebo- treated patient. As a result, the study missed its
endpoints.

The primary endpoint of significant functional improvement
according to mRS evaluated AX200 treated patients relative to
placebo-treated patients. The study recorded no clinical
improvement and did not show any statistically significant
difference. The secondary endpoint of improvement using the NIHSS
relative to placebo-treated patients did also not record a
clinically relevant or statistically significant difference. The
randomized, double-blind AXIS 2 trial enrolled 328 patients in
78 centers throughout Europe.

SYGNIS Pharma will continue to analyse the current data set and the
new data that will become available in the weeks ahead. Full data
will be available in Q1 2012.

For further information please contact:

|Dr. Franz-Werner Haas |
|Senior VP Operations |
|Tel: +49 (0) 6221-454 812 |
|Email: franz-Werner.haas@sygnis.de |

### Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. Some statements included in
this press release, relating neither to proven financial results nor other
historical data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees since given

their very nature they are subject to known and unknown
risks and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions
or implied predictions contained in such statements. SYGNIS does
not undertake to publicly update or revise these statements in
the light of new information or future results or for any other
reason. ###

Further inquiry note:
|Dr. Franz-Werner Haas |
Senior VP Operations
Tel: +49 (0) 6221-454 812
Email: franz-Werner.haas@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English